Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells

Dendritic cells (DCs) are antigen-presenting cells involved in T cell activation and differentiation to regulate immune responses. Lipoimmunogens can be developed as pharmaceutical lipoproteins for cancer immunotherapy to target DCs via toll-like receptor 2 (TLR2) signaling. Previously, we construct...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Shen, Kuan-Yin, Liu, Hsin-Yu, Yan, Wan-Lun, Wu, Chiao-Chieh, Lee, Ming-Hui, Leng, Chih-Hsing, Liu, Shih-Jen
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225995/
https://ncbi.nlm.nih.gov/pubmed/32231003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040810
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items